Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China: The Asian Dragon Lures Foreign Investors

This article was originally published in Start Up

Executive Summary

WuXi PharmaTech's spectacular public offering last summer piqued foreign investors' interest. Top tier VC firms are now investing in contract research organizations, manufacturing plays, and start-ups shifting business operations to China.
Advertisement

Related Content

Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model
Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model,
Investing In China: Views from Windhover's PharmAsia Summit
Emerging Pharma Markets: Adapt, Diversify, and Persist
Sanofi-Aventis Expands R&D Presence In China
A Sign of the Times: Chi-Med's MediPharma Steps Toward Independence
Lilly and Merck Lead the Way With Asian FIPNet Strategies
Pharma's New Follow-On Strategy
Biopharma: Reviewing 2007 to Forecast 2008
Challenges and Opportunities in China's Medical Device Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091532

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel